Last €0.68 EUR
Change Today -0.033 / -4.65%
Volume 426.5K
TIG On Other Exchanges
EN Brussels
As of 11:35 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

tigenix nv (TIG) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - €1.03
52 Week Low
08/1/13 - €0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TIGENIX NV (TIG)

Related News

No related news articles were found.

tigenix nv (TIG) Related Businessweek News

No Related Businessweek News Found

tigenix nv (TIG) Details

TiGenix NV, a biomedical company, develops and commercializes cell therapy products. The company’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. Its lead product, ChondroCelect, is a cell-based product that is used for cartilage repair in the knee. The company is also involved in developing Cx601, which is in Phase III clinical trial for the treatment of complex perianal fistulas in patients suffering from Crohn’s disease; Cx611, an allogeneic eASC product candidate, which has completed a Phase IIa clinical trial for the treatment of rheumatoid arthritis; and Cx621, an allogeneic eASC product candidate that has completed a Phase I trial for the treatment of autoimmune diseases through intra-lymphatic administration. The company has operations in Belgium, the Netherlands, the United Kingdom, and internationally. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium.

56 Employees
Last Reported Date: 03/18/14
Founded in 2000

tigenix nv (TIG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €433.6K
Compensation as of Fiscal Year 2013.

tigenix nv (TIG) Key Developments

TiGenix N.V. Presents at BIO Asia International Conference, Apr-09-2014 10:00 AM

TiGenix N.V. Presents at BIO Asia International Conference, Apr-09-2014 10:00 AM. Venue: Grand Hyatt, Tokyo, Japan.

Swedish Orphan Biovitrum AB (Publ) Enters Partnership with TiGenix NV for the Commercialisation of Chondrocelect

Swedish Orphan Biovitrum AB (publ) announced that the company has acquired the licencing rights to market and distribute ChondroCelect, a cell-based medicinal product for the repair of cartilage defects of the knee, from TiGenix NV. ChondroCelect was the first cell-based product to be approved in Europe. It is currently available for patients and reimbursed in Belgium, the Netherlands and Spain. Sobi will continue to market and distribute the product where it is currently available and will work to expand the product's availability to patients in a much wider area, including the rest of the European Union, Norway, Russia, Switzerland, Turkey, and the countries in the Middle East and North Africa.

TiGenix N.V. Presents at European Smallcap Event, Apr-07-2014

TiGenix N.V. Presents at European Smallcap Event, Apr-07-2014 . Venue: Pullman Tour Eiffel, Paris, France.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TIG:BB €0.68 EUR -0.033

TIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TIG.
View Industry Companies

Industry Analysis


Industry Average

Valuation TIG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.6x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIGENIX NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at